ADCT Company Profile and Key Details

Q: Who are the executives of ADCT?

Amanda HamiltonInvestor Relations OfficerMs. Susan RomanusChief Compliance & Quality OfficerMr. Peter J. Graham Esq.Chief Legal OfficerMs. Jennifer L. HerronChief Commercial OfficerMs. Kimberly PopeSenior Vice President & Chief People OfficerDr. Christopher J. Martin DPHIL, Ph.D.Co-Founder & Non-Executive DirectorMs. Kristen Harrington-SmithChief Commercial OfficerMs. Jennifer CreelChief Financial OfficerDr. Patrick van Berkel Ph.D.Chief Scientific OfficerDr. Joseph Camardo Ph.D.Chief Medical OfficerDr. Michael Mulkerrin Ph.D.Chief Technical Operations OfficerDr. Ameet Mallik M.B.A., M.S.Chief Executive Officer & DirectorMr. David M. GilmanChief Bus. & Strategy OfficerMr. Jose I. Carmona M.B.A.Principal Accounting Officer & Treasurer

NYSE : ADCT

ADC Therapeutics SA

$4.01

0.1+2.56%

At Close 4:00 PM

67.07

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ADC Therapeutics S.A. (ADCT) stock surged +2.56%, trading at $4.01 on NYSE, up from the previous close of $3.91. The stock opened at $3.97, fluctuating between $3.93 and $4.20 in the recent session.

Stock Snapshot

3.91

Prev. Close

496.75M

Market Cap

3.93

Day Low

-2.84

P/E Ratio

-1.41

EPS (TTM)

-1.48

Cash Flow per Share

3.97

Open

123.88M

Number of Shares

4.195

Day High

82.2%

Free Float in %

-1.8

Book Value

947.94K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	4.03	4.20	3.93	4.01	947.94K
Feb 05, 2026	4.03	4.19	3.88	3.91	738.47K
Feb 04, 2026	3.91	4.18	3.79	4.09	857.73K
Feb 03, 2026	3.93	3.99	3.78	3.90	531.34K
Feb 02, 2026	3.58	4.02	3.58	3.90	713.14K
Jan 30, 2026	3.73	3.76	3.55	3.61	754.15K
Jan 29, 2026	3.54	3.81	3.50	3.76	746.08K
Jan 28, 2026	3.60	3.62	3.25	3.54	1.07M
Jan 27, 2026	3.62	3.64	3.52	3.59	655.98K
Jan 26, 2026	3.61	3.64	3.51	3.62	613.04K
Jan 23, 2026	3.76	3.84	3.57	3.61	750.82K
Jan 22, 2026	3.62	3.87	3.58	3.80	501.38K
Jan 21, 2026	3.51	3.62	3.48	3.57	565.66K
Jan 20, 2026	3.53	3.62	3.49	3.52	357.71K
Jan 16, 2026	3.50	3.62	3.44	3.62	754.24K
Jan 15, 2026	3.77	3.84	3.50	3.55	490.35K
Jan 14, 2026	3.70	3.79	3.65	3.71	553.09K
Jan 13, 2026	3.84	3.85	3.69	3.70	504.07K
Jan 12, 2026	3.67	3.89	3.58	3.82	897.98K
Jan 09, 2026	3.62	3.83	3.54	3.66	637.61K

Contact Details

Epalinges, 1066

Switzerland

https://www.adctherapeutics.com 412 165 30200

About Company

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Stock Peers

AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 PTHS

-0.331-1.42%

Pelthos Therapeutics Inc.$22.99 RCUS

1+4.99%

Arcus Biosciences, Inc.$21.03 EVMN

0.65+3.90%

Evommune, Inc.$17.31 ANRO

1.11+7.87%

Alto Neuroscience, Inc.$15.22 BHVN

0.84+7.81%

Biohaven Ltd.$11.60 DNA

1.78+21.39%

Ginkgo Bioworks Holdings, Inc.$10.10 BTX

0.27+4.30%

BlackRock Technology and Private Equity Term Trust$6.55 NUVB

0.08+1.42%

Nuvation Bio Inc.$5.70 ANVS

0.05+2.05%

Annovis Bio, Inc.$2.49

Company Overview

ADC Therapeutics S.A. (NYSE:ADCT) closed at $4.01 USD, gaining $0.10 (2.56%) from the previous close of $3.91. The stock is currently mid-range between its 52-week high and low $1.05 and $4.80. With a market capitalization of about $496.75 million, ADC Therapeutics S.A. is classified as a small-cap and shows higher-than-market volatility (beta ~1.95). Key stats such as the average daily volume over the past year has been around 1.14 million shares, in line with its 52-week average. Headquartered in Epalinges, None, ADC Therapeutics S.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ameet Mallik, the company employs approximately 263 people and listed since May 18, 2020. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 7.67%, SMA50 6.43%, SMA200 20.42%). The stock’s 14-day RSI is 57.89 (neutral), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -16.46% below its high and over 281.9% above its low. Average 10-day trading volume of 779.40 thousand shares is below the 3-month average of 1.04 million, indicating normal recent market interest.

Valuation Metrics

ADC Therapeutics S.A. trades at a P/E ratio of -3.31, slightly below the S&P 500 average, with a price-to-sales ratio of 6.68 and a price-to-book ratio of -2.32 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.8, also above market averages.

Dividend & Fair Value

ADC Therapeutics S.A. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.86. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

ADC Therapeutics S.A. generated EPS of -$1.45 over the past year. Five-year average earnings growth is 1.38%. Wall Street analysts project EPS growth of 23.62% annually over the next five years. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.27. Next year's EPS is expected at $29.16. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $5.00. The high target offers 149.38% upside. The low target suggests 24.69% downside. The mean target is $7.86. This offers 96.01% upside. ADC Therapeutics S.A. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by -24.94%. The prior quarter beat by 38.89%. Over the last six quarters, Apple has recorded several small beats. These include -13.21% in August 06, 2024.

Shareholding & Insider Activity

ADC Therapeutics S.A. has 123.88 million shares outstanding. The public float is 110.03 million shares, elevated short interest at 3.73% of float. This equals 3.83 million shares. The short ratio is 3.87 days. Institutional investors hold 67.95% of the float. Insiders own 13.76%. Redmile Group, LLC holds 3.85 million shares, MALLIK AMEET has 1.17 million shares and Pfisterer Thomas has 213.90 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, ADC Therapeutics SA generated $69.56M in revenue, or $0.85 per share. Gross margin was 96.36%, operating margin -238.63%, and net profit margin -345.11%. Returns are negative, with ROA at -67.66% and ROE at 161.93%.
On valuation metrics, ADC Therapeutics SA trades at a P/E of -3.31, P/S of 6.68 and P/B of -2.32. The current ratio is 4.63 and quick ratio is 4.34. Operationally, the company’s inventory turnover is 0.30 and cash conversion cycle is 773.36 days. Debt-to-equity is -0.49, supported by a cash flow-to-debt ratio of -1.12.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ADC Therapeutics SA posted revenue of $69.56M, down slightly from $209.91M in the prior quarter. Gross profit was $67.03M (margin 96.36%). Operating income was - $165.99M (margin -238.6%). Net income was- $240.05M (EPS - $2.94).
The company ended the quarter with $278.60M in cash and short-term investments, a total debt of $124.38M, and net debt of - $154.22M. Total assets were $354.78M, with equity of - $148.25M. Financials further reflected weakness, with operating cash flow of - $118.69M, free cash flow of - $121.90M, and capital expenditures of - $3.22M.

Price Forecast & Outlook

Our AI price prediction model suggests that ADC Therapeutics S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.0%, with price expected at $4.09 by February 20, 2026, within a range of $3.96 to $4.25 3-Month Outlook: Projected rise of 3.99%, reaching $4.17 by May 06, 2026, with a range of $4.07 to $4.26. 1-Year Outlook: Projected gain of 622.94%, with price at $28.99 by February 05, 2027, within a range of $18.40 to $43.31.

Key Takeaways

ADC Therapeutics S.A. (NYSE:ADCT) shares are flat -0.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ADC Therapeutics S.A. trading at a premium to the broader market with a P/E of -3.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.15, suggesting 252.87% upside. Our AI forecast model points to short-term strength (2.0% over two weeks), a medium-term rise (3.99% over three months), and a longer-term gain (622.94% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ADC Therapeutics S.A. (ADCT) stock price?

ADC Therapeutics S.A. (NYSE: ADCT) stock price is $4.01 in the last trading session. During the trading session, ADCT stock reached the peak price of $4.20 while $3.93 was the lowest point it dropped to. The percentage change in ADCT stock occurred in the recent session was 2.56% while the dollar amount for the price change in ADCT stock was $0.10.

ADCT's industry and sector of operation?

The NYSE listed ADCT is part of Biotechnology industry that operates in the broader Healthcare sector. ADC Therapeutics S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ADCT?

Amanda Hamilton
Investor Relations Officer
Ms. Susan Romanus
Chief Compliance & Quality Officer
Mr. Peter J. Graham Esq.
Chief Legal Officer
Ms. Jennifer L. Herron
Chief Commercial Officer
Ms. Kimberly Pope
Senior Vice President & Chief People Officer
Dr. Christopher J. Martin DPHIL, Ph.D.
Co-Founder & Non-Executive Director
Ms. Kristen Harrington-Smith
Chief Commercial Officer
Ms. Jennifer Creel
Chief Financial Officer
Dr. Patrick van Berkel Ph.D.
Chief Scientific Officer
Dr. Joseph Camardo Ph.D.
Chief Medical Officer
Dr. Michael Mulkerrin Ph.D.
Chief Technical Operations Officer
Dr. Ameet Mallik M.B.A., M.S.
Chief Executive Officer & Director
Mr. David M. Gilman
Chief Bus. & Strategy Officer
Mr. Jose I. Carmona M.B.A.
Principal Accounting Officer & Treasurer

How ADCT did perform over past 52-week?

ADCT's closing price is 281.9% higher than its 52-week low of $1.05 where as its distance from 52-week high of $4.80 is -16.46%.

How many employees does ADCT have?

Number of ADCT employees currently stands at 263.

Link for ADCT official website?

Official Website of ADCT is: https://www.adctherapeutics.com

How do I contact ADCT?

ADCT could be contacted at phone 412 165 30200 and can also be accessed through its website. ADCT operates from Biopole, Epalinges, 1066, Switzerland.

How many shares of ADCT are traded daily?

ADCT stock volume for the day was 947.94K shares. The average number of ADCT shares traded daily for last 3 months was 1.14M.

What is the market cap of ADCT currently?

The market value of ADCT currently stands at $496.75M with its latest stock price at $4.01 and 123.88M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	263
Beta	1.96
Sales or Revenue	$69.56M
5Y Sales Change%	39.196%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ADCT Company Profile and Key Details

ADC Therapeutics SA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics